<DOC>
	<DOCNO>NCT01885585</DOCNO>
	<brief_summary>The objective regulatory Post-Marketing Surveillance Korea reconfirm clinical usefulness Eliquis collecting , review , identify verify safety effectiveness information Eliquis general practice</brief_summary>
	<brief_title>Eliquis Regulatory Post Marketing Surveillance ( rPMS )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Signed data release Patients undergo elective total hip replacement arthroplasty elective total knee replacement arthroplasty Being treated indication approve use Eliquis® Korea Is contraindicate use Eliquis® describe Korean label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>